Association study of CYP3A5 genetic polymorphismwith serum concentrations of carbamazepine in Chinese epilepsy patients
- Author:
Hongmei Meng
;
Jinyan Ren
;
Yudan Lv
;
Weihong Lin
;
Yingjie Guo
- Publication Type:Journal Article
- From:Neurology Asia
2011;16(1):39-45
- CountryMalaysia
- Language:English
-
Abstract:
Objective: To investigate the association between the CYP3A5 genetic polymorphism and the serum
concentrations of carbamazepine (CBZ), to provide guidance for individualized drug dosing. Methods:
Eighty-four epilepsy patients taking CBZ were included in this study. Their clinical data were
recorded and CBZ serum concentrations were measured. The CYP3A5 6986 genetic polymorphism
was assessed using a polymerase chain reaction-restriction fragment length polymorphism (PCRRFLP)
assay. Patients were divided according to genotype into CYP3A5 expressor (CYP3A5*1/*1
genotype and CYP3A5*1/*3 genotypes) and non-expressor groups (CYP3A5*3/*3). The two groups
were compared for the total dose of CBZ, dose of CBZ/kg body weight, serum drug concentration,
dose-corrected serum concentration, and standardized serum concentration. Results: The total dose
of CBZ and the dose of CBZ/kg body weight was higher in the CYP3A5 expressor group than the
non-expressor (P = 0.043 and P = 0.014, respectively). The dose-corrected and standardized serum
concentrations were lower in the CYP3A5 expressor group than the non-expressor (P = 0.001 and
P < 0.001, respectively). There was however, no signifi cant difference in serum drug concentration
between the two groups (P = 0.487).
Conclusions: There was a close relationship between CYP3A5 genetic polymorphism and the serum
concentrations of carbamazepine.
- Full text:P020150731410286478242.pdf
